Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123129) titled 'A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Condition:
Advanced Malignancy
Intervention:
Drug: SHR-7782 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2025
Target Sample Size: 200
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07123129
Published by HT Digital Conte...